Web Analytics

Technology Market Watch Journal


 Sector Insight & Corporate Overviews

of Quality Technology Companies


> Join newsletter, Email:


> Home Page    >  About Us   >  Stock Quotes & Research

Feature article April 14, 2022:


DIAGNOS' AI-Driven Retinal Analysis Technology is in the Process of Transforming Industries


Technology that detects & classifies serious medical conditions in patients with diabetes or cardiovascular issues from an image of the back of the eye; diabetic retinopathy, hypertension retinopathy, stroke, AMD, glaucoma, & more.




  (TSX-V: ADK) (OTCQB: DGNOF) (Frankfurt: 4D4)


Share data, Capitalization, & Corporate info

 Shares Outstanding:  ~69.47 million

 Recently Traded: ~CDN$0.22/share (TSX-V: ADK)

 52 Week High/Low: $0.65 / 0.22

 Current Market Capitalization: ~$16 million CDN

 Corporate Website: www.DIAGNOS.ca



Valuation Commentary: DIAGNOS Inc. (TSX-V: ADK) (OTCQB: DGNOF) (Frankfurt: 4D4) is a Canadian-based medical software technology company that pioneered 'Computer Assisted Retinal Analysis' (CARA), which automatically analyses the retina (located at the back of the eye) using machine learning / artificial intelligence (AI) technology to identify damage caused by diabetes and cardiovascular issues. For the last 7 years DIAGNOS has commercially advanced its first large-scale application of the technology, primarily aimed at preventing diabetic retinopathy. Entering 2022 marks a pivotal time for DIAGNOS as the technology has recently seen several large players in the eyecare sector and medical field commit to large-scale roll-outs, this is putting pressure on others in the sector to consider a similar move and not be left behind. DIAGNOS' technology essentially transforms eyecare centers into Point of Care and wellness diagnostic centers as the CARA platform also is expected to commercially launch several other large-scale applications, including an application for hypertensive retinopathy (launch imminent) and one for stroke prediction (to begin clinical trials on December 6, 2021 in USA). Complicated medical conditions resulting from diabetes, high blood pressure, and potential stroke can be detected by DIAGNOS' algorithms able to interpret detailed imagery of the retina. Since New Look (with 407 locations in Canada) signed on for CARA platform roll-out DIAGNOS' phone has been ringing from around the globe, essentially other industry participants do not want to miss out on a technology whose time has come. Look for an increase in new business announcements to come from the DIAGNOS over the coming months and years. In fact, Essilor Luxottica (Euronext Paris Stock exchange: EL), the largest eyecare company in the world, with EUR$16+ Billion in revenue/annum and ~18,000 locations, signed a MOU with DIAGNOS in August-2021 and is in active negotiations on terms -- this alone has massive latent catalyst potential for upside share price revaluation of ADK.V as details emerge. Specifically DIAGNOS and Essilor are currently negotiating 3 things; 1) contract for the existing platform, 2) Essilor wants DIAGNOS to do a specific development for their line of fundus camera, and 3) Essilor wants access to future applications DIAGNOS will roll out. The fact the largest eyecare company in the world chose DIAGNOS' technology speaks volumes as to where this is headed.


With all the activity DIAGNOS has on the go it appears a low-risk high-reward proposition: ADK.V only has 69.47 million shares outstanding, there are very little warrants left, and insiders & family office own ~40% of the outstanding shares. DIAGNOS has money in the bank, an untapped C$2 million government credit line if needed, has a high-margin SaaS model (it only costs ~4 cents to process an image that it charges between ~C$5 - $10), is expected to be cash flow positive (based on solid contracts) by June-2022, has numerous new business prospects in discussion now, and is expected to see rapid revenue growth. Astute investors connecting the dots about what is unfolding are apt to do well by establishing a long position in ADK.V now.


DIAGNOS Inc. received its first institutional coverage from the independent investment bank / advisory / equity research firm Echelon Capital Markets, its current rating is 'Top Pick', 'Speculative BUY' with a near-term (12 month) target price per common share of DIAGNOS of $1.55 Canadian (or in US dollars: USD$1.23 or in Euros: €1.09) -- click here to view full copy of their latest (January 4, 2022) report. The original initiating report was exceptionally thorough (~40 pages), the analyst contacted multiple industry participants, and recently (November-2021) sat down for an interview [running time 32 min. Youtube] on his reasoning for making it a top pick entering 2022. Note, the analyst share price target is based on the DIAGNOS’ CARA Platform that is currently in use and does not include progress on the Stroke Predictor application that is the subject of clinical trial news – needless to say a much higher share price target is justified if success in the Stroke Predictor clinical trial is demonstrated.

Click to view Analyst update report [PDF] C$1.55/sh. price target



Figure 1. (above) On the left is seen a typical fundus camera image being taken on a patient. On the right is seen a retinal image enhanced with DIAGNOS software, prepped for A.I. auto-detection of pathology & lesion classification. All images world-wide are sent via secure feed to its high security facility in Montreal for processing and quick turn-around. If it detects a risk, the supervised machine learning algorithm separates diabetic retinopathy into 5 clinical diagnoses, the report refers the patient to a retinal specialist doctor, who prescribes the appropriate medication or treatment. DIAGNOS has a SaaS model, it does not sell the software, it protects its proprietary code and database, the software resides in its servers, and everywhere the CARA platform solution is set up it functions as a service.


Revenue Generating Medical Applications - Product Pipeline


Figure 2. (Above) Product pipeline


CARA Platforms 1st large application -- Screening diabetic population to avoid blindness from DIABETIC RETINOPATHY: Status - deployed and in production. The test is via a flash from a standard off-the-shelf fundus camera (a specialized optical microscope with an attached camera), it is quick (only takes seconds), painless, noninvasive, and low cost. The retinal image is securely sent electronically for instant analysis by DIAGNOS' proprietary AI engine algorithms and sizeable database. CARA is Certified in ISO certification, and has multiple regulatory approvals. The CARA platform is advantageous over humans in terms of high-accuracy and consistency (unlike a human, software does not get tired). The technology was pioneered by DIAGNOS Inc. over the last decade, CARA technology is proven and its first large application targeting diabetics is in commercial production use now in 16 countries around the globe. The proprietary AI algo-driven database of DIAGNOS is made up of over 400,000 high-quality case study datasets, making its success unparalleled. Numerous people across the globe owe their eyesight today from having received a heads-up from DIAGNOS' CARA.


DIAGNOS greatly assists in managing the care of at-risk populations. Retinal imaging diagnostic technology is gaining popularity; doctors and specialists strongly endorse the technology as large numbers of people can be seen that otherwise would not be seen. Governments like it as proactively stopping/minimizing debilitating health issues immensely saves money, and pharma (manufacturers and retailers) like it as they sell advanced medication for conditions identified. DIAGNOS has first-mover advantage in its niche and has no serious competition at the moment, there are a handful of private firms connected to academic organizations dabbling in medical retinal analysis tech, and of those only two known private commercial operations are worth noting; however one has essentially shifted away to dermatology since Covid, and the other quite frankly charges too much (i.e. C$25/image compared to C$5 - $10 DIAGNOS charges) and is differently focused.


The share price of ADK.V is apt to rise as the reality of the magnitude developing for DIAGNOS' technology becomes more apparent to the market...


Noteworthy contracts currently in roll-out and related revenue potential:


New Look (Canada) 407 store (currently as of Nov-2021 10 stores have installs, and all 407 should be installed by end of 2022), DIAGNOS is rolling out to perform 10 tests/day/ store @CDN$5 revenue/test = CDN$6.5 Million/yr.

MAGRABI (a group of private hospitals in Saudi Arabia) 32 hospitals (the second CARA install has just occurred, more to come soon), 50 tests/day/site @CDN$5 /test = CDN$2.56 Million/yr.

20/20Now (USA) 65 optometry sites, (installs are starting back up now after experiencing Covid delay), 10 tests/day/site @USD$3/test = USD$624,000/yr.

Chaparral Medical Group (USA) 22 sites, has been a client for several years at one location and is expanding rollout now (installs on the remainder is back on now after experiencing Covid delay), 25 tests/day/site @USD$3/test = USD$528,000/yr.

Opticalia (Latin America) is a franchisee group of optometry stores with 920 franchises, have now installed CARA at 7 locations and aiming to do all 920, 10 tests/day/site, @Euro€3/test = €8.8 Million/yr.

Optica Central (Costa Rica) 65 optometry stores, 10 tests/day/site, @USD$3.50/test = USD$593,600/yr.


Established revenue sources looking to up their game:  Novartis, Quebec Government (RFP 1M patients), Bangladesh Government, Grupo Devlyn with 900+ stores = ?TBD?/yr. ...


REVENUES ARE PROJECTED TO EXCEL: Based on established business, plus the pace of the current new roll-outs (above), we calculate DIAGNOS Inc. should report somewhere between CDN$10M and $20M in revenue in its next fiscal year, comfortably be cash flow positive, and easily grow in revenues every year thereafter based on diabetic retinopathy application alone.


Noteworthy new business prospects - this is a short-list of the most advanced in discussion that DIAGNOS feels closest to closing on:


Essilor International- MoU ~18,000 stores worldwide -- see related August 16, 2021 news release (negotiations underway now).

LMC Endocrinology- 18 diabetic clinics across Canada.

Quest Diagnostics US- One of the largest groups in US with over 300 clinics.

Saudi Government- Through ELM consulting that belongs to the King;500 clinics, 7 M diabetics (fact: ~35% of Saudi Arabia's population has diabetes).

UAE Government- 2M diabetics, Pilot scheduled this year subject to pandemic.

Panama Government- Pilot was done March 2020 to cover 1.4M diabetics.

Kaiser Permanente US- 2.5M diabetics

Mexico Government-7M diabetics, Pilot was done in 2019-2020 over 100,000 patients, just waiting for Covid to calm down before restarting.

Kaiser Permanente US- One of the largest HMO with 2,4000,000 diabetics, post Covid.


Florida Government US- 5.8 M diabetics.


FYIdoctors Canada- 256 stores, mainly in Western Canada.

Salud Digna Mexico- 1M diabetics.


Note: There are many more prospects than itemized above, the number of enquiries of late has dramatically increased -- there is now a shift within the eyecare industry whereby major players see the benefit of becoming more like "Point of Care" and "wellness centers", there is also increased interest from labs, and clinics. Additionally, besides patient wellbeing, the medical clinics and optometrists appear more keen to push a DIAGNOS test as they mark-up the cost, plus the client is essentially locked-in to returning for an annual test or follow-up to the same location to compare results for change in condition.


------ ------ ------      ------ ------ ------      ------ ------ ------


CARA Platforms 2nd large application -- Screening for HYPERTENSIVE RETINOPATHY: Status - in preliminary commercialization. If patients are suffering from hypertension or taking blood pressure medication, using the same retinal image from its CARA platform DIAGNOS can proactively see damage being done to the retina -- a hypertensive patient can develop hypertensive retinopathy, which can lead to vision loss. DIAGNOS can measure retinal vascular tortuosity; your blood vessels are supposed to be nice and straight, as soon as your blood pressure goes higher it puts a lot of pressure on the arteries and veins -- the smaller the blood vessels the quicker the change, so that is why the eyes are best.


Figure 3. (above) CARA (Computer Assisted Retinal Analysis) Artery Vein (AV) Ratio analysis in action and retinal images -- DIAGNOS' cardiovascular retinal imaging looks at micro circulation, the small little vessels. There is a direct relationship between cardiovascular issues and the retina. DIAGNOS' algos focus on the artery-to-vein ratio (AVR), classifying the patterns of blood vessels, and how swollen (or not) they are.


DIAGNOS' new cardiovascular applications will be marketed as an add-on to its now proven and accepted CARA. No retinal imaging competitor can offer anything in the cardiovascular realm, DIAGNOS is uniquely positioned in the market, the level of interest in its hypertension application as an add-on to what DIAGNOS is already offering is enormous.


------ ------ ------      ------ ------ ------      ------ ------ ------


CARA Platforms 3rd large application -- Screening for PROBABILITY OF STROKE: Status - To begin clinical trials with CommonSpirit Health Research Institute starting December 6, 2021. Having a stroke can lead to life-debilitating paralysis. DIAGNOS is starting a clinical trial in the second largest hospital group in the US (CommonSpirits; which has ~137 hospitals and >1,000 clinics, in 21 states) to prove DIAGNOS can predict if an individual will have a stroke using the same fundus camera image of the back of the eye. DIAGNOS is doing a clinical trial study in collaboration with them as they see the CARA platform as an important tool to reduce costs long-term and provide rapid feedback on the effectiveness of individual patient’s medication. If the planned trials for the Stroke Predictor demonstrates the level of accuracy that DIAGNOS has encountered in its development stages, Market Equities Research Group has stated Pharma professionals have told its analyst "...look for shares of ADK.V to trade well above $5/share and the Company to eventually become the subject of buyout. The 'Stroke Predictor' application can state the probability of someone having a stroke in the next two years and it will also tell you why. Success in early detection of cardio vascular issues in such a non-invasive manner for the patient could quickly result in the DIAGNOS CARA platform being a go-to service in a massive market place that currently spends >US$500 Billion a year in drugs and services for cardiovascular and stroke issues. DIAGNOS' technology can also quickly reveal if a patient's medication is working by showing changes in condition (progression or regression). Pharma and the medical community will pay up for this technology and DIAGNOS Inc. will no longer resemble what it is today."


"By 2035, cardiovascular diseases will be the most costly and prevalent killer (if left unchecked), and will place a crushing economic and health burden on the nation's financial and health care systems."


-- Source: Study conducted by RTI International for the American Heart Association

"By 2030, the total global cost of CVD is set to rise from approx. US$863 billion in 2010, to a staggering US$1,044 billion."


-- Source: World Heart Federation


------ ------ ------      ------ ------ ------      ------ ------ ------


Recent Company news of significance


• March 29, 2022 "DIAGNOS Announces Closing of Private Placement and New Marketing Director".


• March 15, 2022 "CAN Health Network and Quebec-Based DIAGNOS Announce Life-Changing Diabetic Retinopathy Screening Program Partnership".


• March 1, 2022 "DIAGNOS Announces Closing of Private Placement".


• February 10, 2022 "DIAGNOS Successfully Completes ISO / MDSAP Audit".


• January 26, 2022 "DIAGNOS Provides Corporate Update for 2021 and Outlook for 2022".


• December 15, 2021 "DIAGNOS will be Attending in San Francisco during the J.P. Morgan Health Care Conference Week to be held from January 10th to 13th, 2022".


• November 23, 2021 "DIAGNOS will start a clinical trial study in the USA commencing December 6th, 2021 for early detection and prevention of Stroke using CARA-STROKE".


• October 28, 2021 "DIAGNOS Delivers World Class Results in the MICCAI2021 Contest: GAMMA".


• September 16, 2021 "DIAGNOS Announces a Multi-Year Contract with Juarez Health & Medical Tourism Cluster".


• September 14, 2021 "DIAGNOS Announces a 3-Year Contract with Cielo Vista Eye Clinic in Mexico".


• September 10, 2021 "DIAGNOS Announces Voting Results of Annual Meeting of Shareholders".


• September 2, 2021 "DIAGNOS Announces a Three-Year Contract Renewal with Optina Diagnostics Providing a Telemedicine Platform to Support their Early Detection of Alzheimer's Disease Test".


• August 16, 2021 "DIAGNOS signs Memorandum of Understanding with Essilor International".


• July 28, 2021 "DIAGNOS Announces a Pilot with Opticalia in Spain".


• July 22, 2021 "DIAGNOS Announces the Official Opening of the AI Assisted Screening Clinic at Magrabi Hospital with the Presence of the Undersecretary of the Ministry of Health of Saudi Arabia".


• July 20, 2021 "DIAGNOS initiates a clinical trial study in the USA for early detection and prevention of Stroke using its new application CARA-STROKE".


• June 15, 2021 "DIAGNOS Announces a Pilot with Hospital Oftalmolσgico Buena Vista Sinaloa".


• June 9, 2021 "IRIS Teams up with DIAGNOS Inc (DGNOF) in a Multi-Year Agreement to Implement Artificial Intelligence Technology with Support From the INVEST-AI Program".


• April 6, 2021 "DIAGNOS (OTCMKTS:DGNOF) Enters into Exclusive Distribution Agreement to Access Massive Global Healthcare Market in DACH Countries and Central Europe of Over 140 Million People".


• March 9, 2021 "DIAGNOS, following a successful Proof-of-Concept (POC) pilot study, is finalising its new application CARA-STROKE to address Stroke prevention and management, a market estimated at $36 Billion".


• March 4, 2021 "DIAGNOS and the third largest optical retailer in Costa Rica Piloting CARA and its Telemedicine technology".


• February 26, 2021 "DIAGNOS Announces Exercise of Stock Warrants and Provides a Cash Update".


• February 24, 2021 "DIAGNOS Announces its Exclusive Strategic Partnership Agreement with Labtician Ophthalmics, a Leader in Canadian and International Eyecare Markets to Address Growing Needs in the Monitoring of Diabetic and Hypertensive Patients".


• February 2, 2021 "DIAGNOS Announces Further Deployment of its AI based CARA Technology in Saudi Arabia".


• January 28, 2021 "DIAGNOS announces the re-opening of its medical testing in Panama".


• January 21, 2021 "DIAGNOS Successfully Completes ISO 13485 / MDSAP Audit".


• January 19, 2021 "DIAGNOS announces a 3-year partnership agreement with the University of Montreal Hospital Centre (CHUM) on the use of Artificial Intelligence".


• January 14, 2021 "DIAGNOS Announces Partnership in Saudi Arabia with Magrabi Hospitals and Centers to Screen Diabetic Patients".


...Click here to view more news releases from source

------ ------ ------      ------ ------ ------      ------ ------ ------


A closer look at DIAGNOS' traditional business (targeting vision loss in diabetics) and how the company sees it growing


Diabetic retinopathy is silently blinding millions of people a year, the market size was valued at USD $8B in 2018 and is expected to witness 6.9% compounded annual growth rate from 2019 to 2025.



Figure 4. (above) - Client Test Referral Pathway -- Because the images can be sent over the internet, the doctor can be in a different physical location confirming the diagnosis.


DIAGNOS' algorithms are capable of
   • Automatic classification by level of severity of DR & DME:
      - State of the art Deep Learning technology.
      - Best in class: sensitivity 94% and specificity 88%.
      - Results in less then 2 seconds.
   • Automatic detection of anomalies in retinal photographs.
   • Validation of lesion with simplified grading sheet (AAO).


Figure 5 (above) Automated triage can help reduce healthcare labor requirements while increasing patient access to quality care and reducing healthcare expenditure.

The diseases targeted by the algorithm include the leading causes of blindness among adults, such as diabetic retinopathy and aged-muscular degeneration. There is an estimated ~500 million people with diabetes worldwide, of that number 0.1% of people with diabetes will lose their vision completely per year if not screened, that translates to 500,000 people per year that will go blind from a curable disease if they are not screened. These diseases are treatable with existing medicine but only if caught in the early stage. However, people at risk are not getting their eyes checked regularly, and therefore going blind unnecessarily, for the following reasons:


A). There is a shortage of retina specialist doctors. There are less than 2000 retina specialists in the US versus nearly 50 million diabetics. Clinical guidelines suggest that every diabetic be screened for diabetic retinopathy once a year, obviously impractical for such a large number to be screened under traditional methods by so few specialists. In less developed countries the ratio of specialists to diabetic population is even worse compared to the US and Canada. By using an algorithm to screen patients, DIAGNOS ensures that only those at risk see a doctor, which relieves congestion in the healthcare system, while improving access to healthcare.


B). Seeing a doctor is expensive. Retina specialists can charge $300+ per visit, but DIAGNOS' software driven procedure charges out at a comparatively nominal cost per visit, in some cases this fee can be paid by a sponsor (such as the pharmaceutical company) rather than the patient.


C). Seeing a doctor is inconvenient. Retina specialists tend to be located in urban areas, and therefore may be inaccessible for rural populations. However, DIAGNOS' system could be installed in Primary Care Facilities, or stores providing low-cost healthcare services, further improving access to basic healthcare.



Figure 6. (above) - Comparison of normal vision vs. what someone with DR might see.


------ ------ ------   ------ ------ ------   ------ ------ 

Below is expanded insight on DIAGNOS Inc. and its technology.

   Content found herein is not investment advice see Terms of Use, Disclosure & Disclaimer.

*Projections, estimates, and assumptions herein are based on journalistic opinion, not Company guidance



Diabetic Retinopathy is a Treatable Disease

  • Early detection and treatment can prevent 85% to 95% of blindness cases.

  • The patient may experience no symptoms until the condition is severe.

  • People who are unscreened are more likely to:
           - Present in the ER.
           - Become blind.
           - Have other complications.

  • People who are screened tend to take better care of their diabetes.

------ ------ ------      ------ ------ -------      ------- ------ ------


Figure 7. (above) - Types of visions related diseases detected via teleretinal screenings


------ ------ ------      ------ ------ -------      ------- ------ ------

Regulatory Compliance:


ISO 13485 : 2016 • CERTIFIED
Cofepris-Mexico • CLEARED

------ ------ ------      ------ ------ -------      ------- ------ ------

Value Propositions of DIAGNOS' Technology:


 for the  



• Convenient non-invasive test.
• Trip to specialist only if necessary.

------ ------ ------ ------ ------ ------

Diabetologist/ GP / Endo

• Higher patient compliance.
• Additional pertinent patient information.


------ ------ ------ ------ ------ ------

Retina Specialist

• Increased focus on treatable cases.
• Increased revenue.


------ ------ ------ ------ ------ ------

Pharmaceutical Company

• Increased drug sales volume.


------ ------ ------ ------ ------ ------

Insurance Company

• Increased patient compliance.
• Decreased health plan expenditure.

------ ------ ------ ------ ------ ------



• Significant cost avoidance mid/long term.
• Positive political optics.


------ ------ ------ ------ ------ ------


------ ------ ------      ------ ------ -------      ------- ------ ------


Deployment of CARA:

DIAGNOS is flexible with regards to screening options; variable formats to deliver the technology



Figure 7. (above) - Deployment Options

------ ------ ------      ------ ------ -------      ------- ------ ------


Revenue Growth Plan


Figure 8. (above) Revenue Model Breakdown


Figure 9. (above) Noteworthy milestones and partnerships over time for DIAGNOS Inc.



DIAGNOS Inc.'s Governance and Management  Skip to top


ADK.V's board of directors and management team has a well rounded combination of people that each contribute expertise in disciplines necessary for a successful organization:


Andrι Larente, President, CEO, and Director

Mr Larente has previously held leading management positions with companies such as Siemens, Syscan International, Newbridge Networks, Legent Corporation, Cognos, Tandem Computers and Honeywell Information Systems.

Dr. Reid MacLellan, MD, MMSC, Director

Dr. MacLellan received his MD diploma from the University of Alabama School of Medicine. Dr. MacLellan also holds a Master in Medical Sciences degree from Harvard Medical School. His primary area of investigation is focused on vascular anomalies. Dr. MacLellan currently serves on different boards of healthcare organizations.


Francis Bellido, Director

Mr. Bellido has spent his career overseeing and leading the development of several organizations in the healthcare industry. He brings sound financial management expertise, deep operating and leadership experience, and a global business perspective that he acquired over 30 years of international experience in the Biosciences, Healthcare and Financial industries. Notably, Mr. Bellido managed a CA$300M life science investment Fund (SGF-Santι) that produced several key players in the Medical Device industry.


Vincent Duhamel, Director

Mr. Duhamel has an established track record in overseeing start-up companies and restructuring operations, as well as leading large investment teams in multi-cultural environments. Mr. Duhamel was recently Vice Chairman of the board of directors of Fiera Capital, a leading independent global asset management firm. Prior to joining Fiera Capital, he held several senior positions in Asia and Canada, including Managing director of Goldman Sachs Asia. Mr. Duhamel has played an active role on several boards and committees, including at the CFA Institute and the Stock Exchange of Hong Kong.


Robert J. Dunn, Director

With 40 years of extensive experience in the insurance business, Mr. Dunn brings expertise in, among others, the financial and communications sectors. From 2017 to 2019, Mr. Dunn held the position of Vice Chairman and Executive Vice President of HUB International Quιbec Ltd.



  • Dr Neil Bressler, Chief - Retina Division, Johns Hopkins Medicine.

  • Dr Jason S. Slakter, M.D. is a board certified retinal and macular disease specialist, Clinical Professor of Ophthalmology at New York University School of Medicine.

------ ------ ------      ------ ------ -------      ------- ------ ------


Note: This list is not intended to be a complete overview of DIAGNOS Inc. or a complete listing of DIAGNOS Inc.'s projects. Technology MarketWatch urges the reader to contact the subject company and has identified the following sources for information:


For more information contact DIAGNOS Inc.'s head office at: Ph (450).678-8882


Company's web site: www.DIAGNOS.ca   SEDAR Filings: URL


Welcome to Technology Market Watch Journal


Technology MarketWatch provides insight into growing and highly prospective technology companies, many which are so often overlooked/flying under the radar, and can provide exceptional potential to richly reward investors. The companies we select offer outstanding prospects and experienced management.



> Free Newsletter/Membership





Content found herein is not investment advice see Terms of Use, Disclosure & Disclaimer. This is a journalistic article and the author is not a registered securities advisor, and opinions expressed should not be considered as investment advice to buy or sell securities, but rather journalistic opinion only. Technical terms used by the writer may be used/expressed in simplified layman terms and should not be relied upon as appropriate for making investment decisions unless the reader contacts the company directly for independent verification.